Across Sub-Saharan Africa, digital health is creating new opportunities to expand access to healthcare, strengthen service delivery and improve health-system performance. Mobile connectivity, cloud-based platforms, telemedicine and point-of-care technologies are changing how health information is generated, shared and used.
Yet an important challenge remains: a digital health solution can perform successfully in a pilot and still struggle to become part of routine healthcare delivery.
The problem is not necessarily the technology. It may be the health ecosystem expected to receive it.
A platform may be technically sound, but its successful integration depends on whether healthcare providers can use it within existing workflows, whether facilities have the necessary infrastructure, whether regulatory and ethical requirements are met, whether financing can support continued operation, and whether communities can access and trust the service.
These considerations become particularly important as digital applications increasingly influence how people obtain and interpret health information. Digital tools can improve access to information, but they must also operate within appropriate clinical governance arrangements. Patients should not be left to carry the responsibility of distinguishing reliable medical guidance from inaccurate, incomplete or inappropriate information. Digital solutions should strengthen access to qualified healthcare professionals and support safe clinical decision-making, rather than inadvertently weaken these safeguards.
For governments, development partners, telecommunications companies, technology providers and investors, the question is therefore not simply whether a digital solution works. It is whether the health ecosystem is prepared to receive, integrate and sustain it.
At Lilis Medical, we are developing Evidence-to-Implementation Research (EIR™) as a prospective approach to understanding health ecosystem readiness before an intervention moves into wider implementation or scale.
Rather than waiting for operational difficulties to emerge after deployment, EIR™ places greater emphasis on examining the conditions that influence whether an innovation can be absorbed, adopted and sustained in its intended setting.
In digital health, this assessment can examine five interconnected areas:
Clinical workflow and workforce readiness: Can healthcare providers use the technology effectively within existing service delivery arrangements? Does it complement clinical judgement, strengthen provider–patient relationships and fit the daily workflows of frontline teams?
Regulatory and ethical alignment: Are the relevant regulatory requirements, clinical governance arrangements, patient safety safeguards and health-data protection measures addressed before implementation?
Infrastructure and interoperability: Do facilities and health institutions have reliable connectivity, appropriate hardware, technical support and systems capable of exchanging and managing information securely?
Financing and sustainability: Is there a credible pathway for financing ongoing operations, maintenance, technical support and service delivery beyond initial investment or donor-funded pilots? Can the proposed model work within existing public financing, insurance or other appropriate funding arrangements?
Community access, trust and health literacy: Can intended users access and navigate the service? Is it responsive to their circumstances, language and health-information needs? Are appropriate safeguards in place to ensure that digital access does not create new barriers or transfer clinical responsibilities to patients?
These areas help bring clinical, institutional, regulatory, financial and community considerations into the investment and implementation discussion before wider deployment.
For digital health investors and implementing partners, the implications are significant.
Understanding readiness before scale can help identify where additional investment, adaptation, partnerships or regulatory engagement may be necessary. It can also help distinguish between a technology that needs further development and one that is technically ready but requires changes in the receiving health ecosystem.
This distinction matters. Without it, organisations risk attributing implementation difficulties to the technology alone, overlooking the institutional and health-ecosystem conditions that determine whether it can deliver lasting value.
For telecommunications companies and digital infrastructure providers entering the health sector, this perspective is particularly relevant. Connectivity is an essential enabler, but connectivity alone does not establish clinical integration, provider uptake, regulatory alignment or sustainable service delivery. These require engagement with the wider health ecosystem.
EIR™ offers a way to bring these considerations into earlier decision-making. Its development reflects a broader proposition: health innovation should be assessed not only for what it can do, but also for the conditions required for it to work in practice.
The future of digital health in Africa will depend not only on the availability of innovative technologies, but also on the ability of health ecosystems to integrate them responsibly and sustainably.
At Lilis Medical, we work at the intersection of health research, systems strengthening, innovation and strategic advisory. We collaborate with governments, research institutions, development partners and private-sector innovators to translate evidence and health ecosystem realities into informed implementation strategies.
Through the continued development of EIR™, we seek to contribute to a more deliberate approach to health innovation investment—one that considers readiness before scale and places sustainable integration alongside technological performance.
Because successful digital health innovation is not measured by deployment alone. It is measured by whether it becomes a safe, accessible and sustainable part of healthcare delivery.
From County Health Indicators to Local Evidence: Adolescent Health in Busia County, Kenya
Recent reporting around World Contraception Day has highlighted persistent adolescent sexual and reproductive health (ASRH) challenges in Busia County. Figures reported by Daily Nation indicate an adolescent pregnancy rate of 16.9% in Busia, compared with 15.5% nationally, while reported contraceptive uptake was 47% in the county against 60% nationally.
These indicators raise an important question: how can health systems translate population-level data into locally informed decisions about adolescent-responsive services?
A preliminary review of available facility-level records for July 2025–June 2026 offers an additional perspective:
Nambale Sub-County: 644 recorded adolescent antenatal care (ANC) enrolments and 354 sexually transmitted infection (STI) presentations.
Matayos Sub-County: 1 recorded adolescent ANC enrolment and no recorded STI presentations.
These are recorded service counts, not estimates of adolescent pregnancy or contraceptive use. The differences warrant further examination of data completeness, reporting practices, service availability and utilisation before conclusions can be drawn about local needs or health-system capacity.
For Lilis Medical, this illustrates an important principle underpinning our developing Evidence-to-Implementation Research (EIR™) approach: population-level indicators and facility-level records provide complementary perspectives, but neither alone offers a complete picture of the health system in which an intervention must be implemented.
Understanding that context requires attention to the quality and completeness of available evidence, the realities of frontline service delivery, the experiences of adolescents and the institutional conditions needed to sustain effective interventions.
We are grateful to Dave Sibeyo for his technical contribution to this work and recognise the importance of constructive collaboration among county health teams, healthcare providers, communities and research partners.
At Lilis Medical, we are interested not only in whether an intervention works, but also in what the receiving health system needs to introduce, integrate and sustain it.
Better implementation begins with better understanding of context.
Sources: Daily Nation reporting on adolescent pregnancy and contraceptive uptake in Busia County, as linked in the accompanying source material. Facility-level figures are from a preliminary review of available records and require validation.
#AdolescentHealth #ASRH #BusiaCounty #HealthSystems #ImplementationResearch #EvidenceToImplementation #LilisMedical
A recent Daily Nation report on Kenya’s family-planning programme highlights a challenge that extends beyond contraceptive commodities or the immediate availability of funding: what happens to a health intervention when the financing environment that supported it changes?
The question matters because health interventions do not operate in isolation.
They enter health ecosystems with existing policies, institutions, workforces, financing arrangements, supply chains, data systems and communities. Their ability to continue delivering value depends not only on whether the intervention works, but also on whether the ecosystem receiving it can absorb and sustain it.
Kenya’s current family-planning financing pressures make this visible.
When external or programme-specific financing supports commodities, service delivery, workforce capacity, data systems or community engagement, those resources can become part of the operating environment around an intervention. When the financing changes, dependencies that may have been less visible during implementation can suddenly become critical.
This is not unique to family planning.
It is a question that can arise across health programmes and across countries.
Health innovation often follows a familiar pathway.
Evidence is generated. An intervention is evaluated. Regulatory and policy decisions follow. Funding is secured. Implementation begins. Additional resources support training, procurement, technical assistance, monitoring and evaluation.
During the funded period, the intervention may perform well.
But success within a funded programme does not necessarily demonstrate that the intervention has become sustainable within the health system.
What happens when the grant ends?
Can the health system finance the commodities or technologies?
Can the existing workforce continue delivering the intervention?
Are procurement and supply-chain arrangements embedded within routine systems?
Can the data required for monitoring and decision-making continue to be generated?
Is there institutional ownership?
Are the necessary policies and regulations in place?
Will communities continue to use and support the intervention?
And can the system adapt when circumstances change?
These questions are often treated as sustainability questions at the end of an implementation period.
Perhaps they need to be asked much earlier.
An intervention can have strong evidence of effectiveness and still encounter difficulties during adoption.
It can have regulatory authorization, committed partners and several years of implementation funding, yet remain dependent on structures that were created specifically for the project.
The intervention itself may not be the problem.
The receiving ecosystem may simply not yet have the conditions required for sustainable integration.
This distinction matters.
If readiness is assessed only after implementation has begun—or when external financing is coming to an end—there may be limited opportunity to address structural constraints before they affect continuity.
A prospective approach asks a different question:
Before introducing or scaling an intervention, what does the receiving health ecosystem need to be able to do for that intervention to become sustainable?
Financing is clearly important. But financing is only one component of readiness.
A health ecosystem may have funding and still lack the workforce, governance, procurement systems, data infrastructure or institutional arrangements necessary to sustain an intervention.
Conversely, an intervention may be technically feasible but require changes in financing or policy before it can be integrated into routine services.
Understanding these relationships requires looking across the ecosystem.
This includes:
Governance and policy: Is there sufficient alignment, ownership and accountability?
Regulatory readiness: Can the intervention be appropriately authorized, monitored and governed?
Workforce: Are the skills, staffing and incentives available to support delivery?
Operational capacity: Can routine systems absorb the intervention?
Data and digital infrastructure: Can the system generate and use the information required to monitor performance?
Financing: Is there a credible pathway beyond the initial implementation funding?
Institutional capacity: Is ownership embedded within institutions that will remain after the project ends?
Community and stakeholder readiness: Is there sufficient understanding, acceptance and engagement to support sustained use?
These conditions interact.
A financing gap can expose a supply-chain weakness. A workforce constraint can limit adoption. Weak data systems can make it difficult to demonstrate value or identify problems. Lack of institutional ownership can leave an intervention dependent on external technical assistance.
The result is an ecosystem problem, not simply a funding problem.
At Lilis Medical, we are developing the Evidence-to-Implementation Research (EIR™) methodology around this broader question.
EIR treats the receiving health ecosystem as an important unit of inquiry.
Rather than asking only whether an intervention works, it asks whether the ecosystem expected to receive it is positioned to absorb, implement, adopt, monitor, adapt and sustain it.
The purpose is not to predict that an intervention will succeed or fail.
It is to generate useful intelligence early enough to identify the conditions that may influence its translation into routine health practice.
This creates an important shift in perspective.
Instead of treating sustainability as something to be demonstrated when a programme is ending, health-ecosystem readiness can be examined prospectively, before major implementation and scale decisions are made.
Kenya’s family-planning financing situation provides a concrete illustration of a broader issue.
Across countries, health systems are managing changing financing environments, competing priorities and increasing expectations to sustain programmes within domestic systems.
The specific pressures will differ by country, intervention and health-system context.
But the underlying question remains relevant:
When the conditions that enabled an intervention to start change, is the receiving health ecosystem prepared for what comes next?
That question deserves to be part of health innovation and implementation planning from the beginning—not added only when funding becomes uncertain.
The goal should not simply be to introduce interventions successfully.
It should be to understand what allows evidence-based interventions to become embedded, adaptable and sustainable within the systems that ultimately have to carry them forward.
Does the intervention work?
Is the receiving health ecosystem ready to make it work—and keep it working when the original conditions change?
Lilis Medical Insight
Evidence-to-Implementation Research™
Recent developments in the US Food and Drug Administration (FDA)’s approach to therapeutic approval—including circumstances in which a single adequate and well-controlled clinical trial may be sufficient when supported by other confirmatory evidence—illustrate the continued evolution of the evidentiary pathway from clinical development to regulatory decision-making.
As evidence-generation pathways evolve and translational timelines shorten, the characteristics of the receiving health environment become increasingly relevant to what happens after regulatory authorization. Introducing sophisticated therapeutics, diagnostics, and other health technologies into routine clinical practice requires more than product availability. It requires alignment with the infrastructure, workflows, workforce, financing mechanisms, data systems, governance structures, and community contexts in which the intervention will ultimately be used.
A prospective health-ecosystem readiness assessment can establish a structured baseline before product introduction. Such an assessment examines whether clinical workflows can accommodate the intervention, whether frontline health workers have the required capabilities, whether financing and procurement arrangements can sustain use, whether data systems can capture relevant outcomes, and whether institutional and community structures are positioned to support adoption and continued use.
This becomes particularly important where post-authorization evidence and longitudinal Real-World Evidence (RWE) contribute to ongoing regulatory assessment. The value of RWE depends not only on the quantity of data generated, but also on the reliability, completeness, traceability, and contextual integrity of the underlying routine health-system data. Prospective assessment of receiving environments can therefore include examination of whether routine clinical documentation and information systems are capable of generating data consistent with internationally recognized data-integrity principles, including ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available).
The methodological implication is important: the receiving health ecosystem is not simply the destination for an approved product; it is part of the environment in which the product’s post-authorization evidence is generated. Prospective readiness assessment can therefore provide a structured means of identifying and addressing system-level constraints before introduction, while establishing a baseline against which subsequent adoption, implementation, evidence generation, and integration can be examined.
Viewed this way, regulatory science and implementation readiness are not separate stages of the innovation pathway. They are connected components of a longer evidence-to-adoption continuum in which the capacity of the receiving ecosystem can influence both the sustainability of health-product adoption and the quality of the real-world evidence generated after introduction.
Making effective health services available is an important first step. But what happens next matters just as much. For health interventions to make a lasting difference, the health ecosystems receiving them must be ready to support, deliver and sustain them.
This is particularly important in sub-Saharan Africa, where health needs are diverse and evolving. Adolescent sexual and reproductive health (ASRH) remains a critical priority, alongside the need for accessible, long-term palliative care. These priorities affect people at different stages of life, each with distinct needs. Whatever their age or health circumstances, people deserve compassionate, responsive and continuous care.
The Evidence-to-Implementation Research (EIR™) framework considers four connected dimensions:
Provider capabilities: Do existing health workers have the skills, knowledge and support they need? Are roles across levels of care clearly understood? In long-term palliative care, how do specialists and primary care physicians work together? Who coordinates follow-up and links facility-based services with the community? Primary care physicians help maintain continuity, address broader health needs and coordinate referrals beyond specialist consultations.
Institutional capacity: Are resources, workflows, referral pathways and support structures in place?
Community readiness: Are services accessible, acceptable and responsive to the needs and circumstances of the people they serve?
Health-system enablers: Do financing, policies, governance and monitoring arrangements support continuity over time?
These dimensions apply across health priorities. In ASRH, adolescent-friendly services depend on existing providers being able to respond appropriately to young people's needs, supported by accessible services and welcoming community environments. Similarly, long-term palliative care requires coordination between health facilities, primary care providers and community-based services to maintain continuity and respond to changing needs.
At Lilis Medical, we believe successful health innovation begins with understanding the health ecosystem in which it must work. EIR™ is being developed to make that understanding more deliberate, helping translate evidence into services that respond to real needs and make a lasting difference.